NEW YORK (Reuters Health) – In patients with chronic renal failure treated with recombinant human erythropoietin, the formation of neutralizing antierythropoietin antibodies can result in the development of pure red-cell aplasia, European investigators report in The New England Journal of Medicine for February 14.
Dr. Nicole Casadevall, of the Hopital Hotel-Dieu in Paris, and colleagues identified 13 chronic dialysis patients who developed severe transfusion-dependent anemia between 1998 and 2000 following an initial hematologic response to epoetin. The diagnosis of red-cell aplasia was based on the absence of erythroid cells in bone marrow or of circulating reticulocytes.
Twelve of the patients had been treated with epoetin-alpha and one with epoetin-beta. The severe anemia developed after 3 to 67 months of treatment.
After epoetin treatment was discontinued, six patients recovered some erythropoietic function of their own after being treated with immunosuppressants or a renal allograft. Three remain dependent on transfusions more than 2 years later. The remaining four patients also still require transfusions, but their followup has been too short to determine their clinical course. …
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!